CIK 0001512762 · Accelerated filer<br>Smaller reporting company
Coherus Oncology, Inc.
Sign in to watch- Ticker
- CHRS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 273615821
- Phone
- (650) 649-3530
- Business address
- C/O DENNIS M. LANFEAR, 333 TWIN DOLPHIN DR, SUITE 600, REDWOOD CITY, CA, 94065
- Former names
- Coherus BioSciences, Inc., BioGenerics, Inc.
- 4 Open-market sale Director sold 200,000 shares at $17.15 ($3,430,020)
- SC 13G/A Stake Amended Statement of Ownership
- 8-K Event Shareholder vote results
- 4 Open-market sale Chief Financial Officer sold 1,278 shares at $17.66 ($22,569)
- 4 Open-market sale Chief Operating Officer sold 3,093 shares at $17.17 ($53,107)
- CT ORDER Other Confidential Order
- DEFA14A Proxy Proxy Materials
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Open-market sale Chief Operating Officer sold 10,150 shares at an average $16.30 ($165,400)
- 8-K Event Material agreement · New debt or obligation · Unregistered share sale · Other events
- 8-K Event Material agreement · Results of operations · Other events
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 4 Open-market sale Director sold 118,066 shares at an average $20.12 ($2,375,409)
- 10-K Report Annual Report
- 8-K Event Results of operations
- 4 Open-market sale Chief Financial Officer sold 3,159 shares at $22.33 ($70,552)
- 4 Open-market sale Chief Operating Officer sold 10,000 shares at an average $21.64 ($216,390)
- SC 13G/A Stake Amended Statement of Ownership
Page 22 of 47 · 923 filings